Skip to main content
Optimi Health Corp. logo

Optimi Health Corp. — Investor Relations & Filings

Ticker · OPTI ISIN · CA68405H1001 LEI · 98450063FDFF8UD3Q652 CSE Manufacturing
Open in API
Filings indexed 276 across all filing types
Latest filing 2024-08-30 Regulatory Filings
Country CA Canada
Listing CSE OPTI

About Optimi Health Corp.

https://www.optimihealth.ca/

Optimi Health Corp. is a GMP-certified pharmaceutical drug manufacturer and end-to-end drug researcher licensed to produce and supply controlled psychedelic substances. The company specializes in the production of MDMA and psilocybin, primarily supporting psychedelic-based mental health treatments. Additionally, Optimi operates a vertically integrated functional mushroom brand, developing scalable, natural mushroom formulations aimed at the health and wellness sector. This structure allows the company to serve both regulated pharmaceutical supply chains and consumer wellness markets.

Recent filings

Filing Released Lang Actions
Interim financial statements/report – English.pdf
Regulatory Filings
2024-08-30 English
News release - English.pdf
Regulatory Filings
2024-08-28 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 100% confidence The document is titled 'Form 45-106F1 Report of Exempt Distribution' and contains detailed information about securities distribution, including issuer details, underwriter information, distribution dates, purchaser information, types of securities distributed, compensation related to the distribution, and directors/executive officers of the issuer. This form is a regulatory filing used to report exempt distributions of securities, typically filed with Canadian securities regulators. It is not an annual report, earnings release, or any other financial report but a specific regulatory disclosure about securities distribution. The document is lengthy (15,000 characters) and contains substantive data about the distribution event, but it is not a financial report or management discussion. It fits best under Regulatory Filings (RNS) as it is a compliance document reporting exempt distribution under securities law.
2024-08-26 English
Material change report - English.pdf
Capital/Financing Update Classification · 100% confidence The document is a FORM 51-102F3 MATERIAL CHANGE REPORT filed by Optimi Health Corp. It details a material change event, specifically the closing of the first tranche of a non-brokered private placement financing. The report includes the date of the material change, a summary and full description of the financing transaction, and references to applicable securities regulations (e.g., MI 61-101). The content focuses on a capital raising event and related securities issuance, which aligns with updates on company fundraising and capital structure changes. The document is not an annual or quarterly report, audit report, or earnings release, nor is it a voting result or management change announcement. It is a regulatory filing specific to a material change event related to financing. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (7,214 characters) and detailed content confirm it is the report itself, not just an announcement of a report.
2024-08-16 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing several corporate developments by Optimi Health Corp., including the completion of an inaugural export of MDMA capsules to Australia, receipt of export permits for psilocybin shipment to New Zealand, influence on Australian regulatory framework, and the closing of the first tranche of a non-brokered private placement. The document includes details about the private placement financing, including the number of units issued, pricing, and related party transactions. There are no financial statements, comprehensive financial data, or detailed management discussion of financial results. The document is primarily an update on corporate activities and financing, not a full financial report or earnings release. It is not a regulatory filing or certification letter. Given the focus on financing activities and capital raising, the document best fits the category of Capital/Financing Update (CAP). The document length (8260 characters) is sufficient to contain substantive information, not just an announcement of a report publication or a brief notice.
2024-08-16 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a non-binding Letter of Intent (LOI) between two companies, Optimi Health Corp. and Psyence Biomedical Ltd., regarding a potential future collaboration for psilocybin drug development. It contains no financial statements, no regulatory filings, no voting results, no management or board changes, no earnings data, and no detailed financial or operational reports. The document is primarily a corporate announcement about a strategic partnership intention, not a formal report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or any other detailed financial or governance report. It is a general corporate announcement about a business development and forward-looking statements. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous corporate announcements that do not fit other specific categories.
2024-08-13 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.